You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

CLINICAL TRIALS PROFILE FOR DOXAZOSIN MESYLATE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DOXAZOSIN MESYLATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 ↗ Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 1985-08-01 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT01003886 ↗ A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH) Completed Pfizer 2009-05-01 This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
NCT01003886 ↗ A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH) Completed Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 2009-05-01 This study aims to assess the safety, tolerability and efficacy of Doxazosin GITS in Filipino patients diagnosed with Benign Prostatic Hyperplasia (BPH) under the usual clinical care setting.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DOXAZOSIN MESYLATE

Condition Name

Condition Name for DOXAZOSIN MESYLATE
Intervention Trials
Cardiovascular Diseases 1
Heart Diseases 1
Hypertension 1
Prostatic Hyperplasia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DOXAZOSIN MESYLATE
Intervention Trials
Cardiovascular Diseases 1
Prostatic Hyperplasia 1
Hyperplasia 1
Vascular Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DOXAZOSIN MESYLATE

Trials by Country

Trials by Country for DOXAZOSIN MESYLATE
Location Trials
Philippines 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DOXAZOSIN MESYLATE

Clinical Trial Phase

Clinical Trial Phase for DOXAZOSIN MESYLATE
Clinical Trial Phase Trials
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DOXAZOSIN MESYLATE
Clinical Trial Phase Trials
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DOXAZOSIN MESYLATE

Sponsor Name

Sponsor Name for DOXAZOSIN MESYLATE
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 1
University of Minnesota 1
University of Minnesota - Clinical and Translational Science Institute 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DOXAZOSIN MESYLATE
Sponsor Trials
Other 2
Industry 2
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.